13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001746382
Total reported value
$47.5M
$47.5M
77 檔
227.2%
The Q3 2024 SEC filing reveals that Altium Capital Management LLC held a total portfolio value of $47.5M, covering 77 public equity positions.
During Q3 2024, Altium Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | Stock-Other | 8.90% | — | -4.20% | |
| 2 | ADMA | Adma Biologics Inc | Stock-Healthcare | 8.00% | — | -9.93% | |
| 3 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 6.25% | — | +107.57% | |
| 4 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 4.31% | — | — | |
| 5 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.29% | — | +2.61% | |
| 6 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 3.47% | — | +46.25% | |
| 7 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.32% | — | -20.21% | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.16% | — | — | |
| 9 | GKOS | Glaukos CORP | Stock-Healthcare | 2.95% | — | — | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 2.79% | — | -31.58% | |
| 11 | MMSI | Merit Medical Systems Inc | Stock-Healthcare | 2.47% | — | — | |
| 12 | RZLT | Rezolute Inc | Stock-Other | 2.43% | — | — | |
| 13 | PCVX | Vaxcyte Inc | Stock-Other | 2.42% | — | — | |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.36% | — | — | |
| 15 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.35% | — | +3.28% | |
| 16 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 2.25% | — | -23.00% | |
| 17 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.08% | — | -14.02% | |
| 18 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.02% | — | — | |
| 19 | SVRA | Savara Inc | Stock-Other | 1.97% | — | -1.25% | |
| 20 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.88% | — | — | |
| 21 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.71% | — | — | |
| 22 | EOLS | Evolus Inc | Stock-Other | 1.69% | — | — | |
| 23 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.67% | — | — | |
| 24 | RXST | Rxsight Inc | Stock-Other | 1.63% | — | — | |
| 25 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.53% | — | +16.00% | |
| 26 | SKYE | Skye Bioscience Inc | Stock-Other | 1.51% | — | -2.59% | |
| 27 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 1.48% | — | — | |
| 28 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.28% | — | — | |
| 29 | LUNG | Pulmonx CORP | Stock-Other | 1.22% | — | — | |
| 30 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.18% | — | — | |
| 31 | KROS | Keros Therapeutics Inc | Stock-Other | 1.18% | — | — | |
| 32 | REAL | Realreal Inc/the | Stock-Other | 1.17% | — | +1.58% | |
| 33 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.14% | — | +51.48% | |
| 34 | BHVN | Biohaven Ltd. | Stock-Other | 1.10% | — | — | |
| 35 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.07% | — | -12.35% | |
| 36 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.90% | — | — | |
| 37 | OTLK | Outlook Therapeutics Inc | Stock-Other | 0.85% | — | +7.92% | |
| 38 | VCEL | Vericel CORP | Stock-Other | 0.85% | — | — | |
| 39 | HELP | Cybin Inc | Stock-Other | 0.83% | — | — | |
| 40 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.81% | — | — | |
| 41 | OCGN | Ocugen Inc | Stock-Other | 0.69% | — | — | |
| 42 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.59% | — | -65.22% | |
| 43 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.57% | — | — | |
| 44 | ANVS | Annovis Bio | Stock-Other | 0.56% | — | +52.22% | |
| 45 | VERUEUR | Veru Inc | Stock-Other | 0.46% | — | -10.90% | |
| 46 | ATRC | Atricure Inc | Stock-Other | 0.45% | — | — | |
| 47 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.32% | — | — | |
| 48 | ✓ | Envveno Medical CORP | Stock-Other | 0.24% | — | — | |
| 49 | OVASUSD | Tempest Therapeutics Inc | Stock-Other | 0.22% | — | — | |
| 50 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.21% | — | — |
According to official SEC Form 13F filings, Altium Capital Management LLC reported a total U.S. public equity portfolio value of $47.5M across 77 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VERA, ADMA, SRPT) accounted for 227.2% of total reported equity market value during Q3 2024.
During Q3 2024, Altium Capital Management LLC's top holdings by market value included VERA (8.9%)、ADMA (8.0%)、SRPT (6.3%). The largest single position, VERA, represented 8.9% of total portfolio value.
In Q3 2024, Altium Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.